Avacta Group plc (AVCT) AI Stock Analysis

• Market Cap: £266.56M
• Dividend Yield: N/A
• Average Volume (3M): 3.07M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.03
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 154
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.04
• Shares Outstanding: 436,445,680
• 10 Day Avg. Volume: 4,236,507
• 30 Day Avg. Volume: 3,069,625
• PEG Ratio: -0.04
• Price to Book (P/B): 17.61
• Price to Sales (P/S): 1446.46
• P/FCF Ratio: -6.83
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £99.00
• Price Target Upside: 52.31% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -4.85
• Revenue Forecast (FY): £118.60M

• Rating: 42 Neutral
• Price Target: 62.00p ▼(-4.62% Downside)

Avacta Group plc's overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. While there is some progress in clinical programs, financial constraints and lack of partnerships remain significant risks. The stock's valuation is unattractive due to negative earnings and no dividend yield.

Positive Factors

Clinical Program Progress

The advancement of faridoxorubicin to Phase Ib with promising data indicates potential for successful therapeutic development, enhancing long-term growth prospects.

Strategic Collaborations

Strategic collaborations like with Tempus validate Avacta's technology and expand market opportunities, potentially accelerating product development and revenue growth.

Encouraging Preclinical Data

Positive preclinical results for FAP-exatecan suggest strong therapeutic potential, supporting long-term pipeline development and competitive positioning in oncology.

Negative Factors

High Leverage

High leverage increases financial risk and limits flexibility, potentially impacting Avacta's ability to invest in growth initiatives and manage economic downturns.

Cash Burn Issues

Ongoing negative cash flow indicates operational inefficiencies and reliance on external funding, which may constrain long-term sustainability and growth.

Uncertainty in Partnerships

The lack of secured partnerships limits Avacta's ability to expand its development activities and secure necessary funding, posing a risk to future growth.

Avacta Group plc Business Overview & Revenue Model

Company Description

Avacta Group plc is a biotechnology company based in the UK that focuses on developing innovative therapies and diagnostics for various diseases, including cancer. The company operates primarily in the life sciences sector, utilizing its proprietary Affimer technology, which is a platform for the development of therapeutic and diagnostic products. Avacta's core offerings include Affimer proteins that can be used for both research and therapeutic applications, as well as its development of a novel cancer immunotherapy and diagnostic tests for COVID-19 and other diseases.

How the Company Makes Money

Avacta Group plc generates revenue through multiple streams, including the sale of Affimer technology and related products to research institutions and pharmaceutical companies. The company also earns revenue by entering into collaborations and licensing agreements with various partners, which may include upfront payments, milestone payments, and royalties on future sales. Significant partnerships with larger pharmaceutical firms can enhance Avacta's research capabilities and accelerate the development of its therapies, thereby contributing to its revenue growth. Additionally, revenues may be derived from its diagnostic products, particularly in response to ongoing health crises such as the COVID-19 pandemic, where the demand for rapid testing solutions has surged.

Avacta Group plc Financial Statement Overview

Summary

Avacta Group plc faces significant financial challenges, with negative profitability, high leverage, and inconsistent revenue growth. The company relies heavily on external financing, indicating a precarious financial position.

Income Statement

Avacta Group plc shows significant revenue volatility with substantial net losses over the years. Gross profit margin in the latest report is 100% due to negligible cost of goods sold. However, the net profit margin is deeply negative, and EBIT and EBITDA margins are also negative, indicating operational inefficiencies. Revenue growth has been erratic, recently declining sharply, reflecting inconsistent business performance.

Balance Sheet

The balance sheet reveals high leverage with a debt-to-equity ratio increasing over time, posing financial risk. The equity ratio has also weakened significantly, indicating diminished financial stability. Return on equity is negative due to consistent net losses. Overall, the balance sheet highlights substantial financial challenges and risks.

Cash Flow

Cash flow analysis shows negative operating cash flow consistently over the years, with free cash flow also negative, indicating cash burn issues. The free cash flow to net income ratio remains unfavorable, reflecting poor cash generation relative to losses. Financing cash flow is positive, suggesting reliance on external funding to support operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	56.00K	113.00K	2.85M	9.65M	2.94M	2.14M
Gross Profit	-682.00K	113.00K	2.84M	4.23M	-2.50M	-973.00K
EBITDA	-12.03M	-17.62M	-14.12M	-34.78M	-26.69M	-16.40M
Net Income	-17.02M	-52.84M	-24.95M	-36.94M	-26.32M	-18.89M
Balance Sheet
Total Assets	29.24M	48.27M	73.19M	92.65M	47.00M	67.46M
Cash, Cash Equivalents and Short-Term Investments	12.64M	12.87M	16.63M	41.78M	26.19M	47.91M
Total Debt	20.40M	22.93M	23.51M	62.94M	1.70M	2.04M
Total Liabilities	29.09M	38.99M	51.39M	74.21M	5.78M	5.53M
Stockholders Equity	144.00K	9.28M	21.80M	18.44M	41.22M	61.93M
Cash Flow
Free Cash Flow	-13.55M	-23.94M	-16.13M	-17.03M	-21.82M	-12.31M
Operating Cash Flow	-13.51M	-23.60M	-14.87M	-16.43M	-20.51M	-10.64M
Investing Cash Flow	8.77M	-1.43M	-9.00M	-25.04M	18.70M	-21.90M
Financing Cash Flow	666.00K	26.09M	-1.30M	56.90M	232.00K	51.65M

Avacta Group plc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 65.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AVCT, the sentiment is Negative. The current price of 65 is above the 20-day moving average (MA) of 64.66, below the 50-day MA of 71.67, and above the 200-day MA of 50.85, indicating a neutral trend. The MACD of -3.65 indicates Negative momentum. The RSI at 41.81 is Neutral, neither overbought nor oversold. The STOCH value of 77.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:AVCT.

Avacta Group plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AREC	56 Neutral	£32.47M	-3.89	-204.29%	―	3.31%	21.91%
PRTC	55 Neutral	£312.26M	9.05	15.04%	―	1231.50%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SCLP	49 Neutral	£116.75M	-8.52	―	―	―	-94.12%
AVCT	42 Neutral	£266.56M	―	―	―	―	―
NFX	42 Neutral	£6.12M	-0.67	-153.80%	―	―	-616.67%
4BB	41 Neutral	£91.36M	-5.94	-209.34%	―	198.49%	-26.66%

Avacta Group plc Corporate Events

Avacta Unveils Promising Data for Tumor-Targeted Cancer Therapy FAP-Exd

Avacta Group plc has released promising preclinical pharmacology data for FAP-Exd (AVA6103), a tumor-activated drug designed to deliver a highly potent topoisomerase I inhibitor directly to tumors. Key findings highlighted include enhanced tumor-specific cytotoxicity, sustained drug release over five days within tumors, and durable antitumor responses in preclinical models—signifying potential benefits over conventional therapies. The use of AI in clinical trial design has further optimized development and selection of patient populations, positioning the drug for a fast-track Phase 1 trial in early 2026, with significant implications for addressing unmet needs in oncology.

The most recent analyst rating on (GB:AVCT) stock is a Hold with a £81.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.

Avacta’s Faridoxorubicin Shows Promising Results in Salivary Gland Cancer Trials

Avacta Group PLC announced promising Phase 1b clinical trial results for its drug faridoxorubicin (AVA6000) in treating salivary gland cancer (SGC), showing a 90% disease control rate across Phase 1a and 1b trials. The trial demonstrated clinically meaningful tumor shrinkage and prolonged progression-free survival, reinforcing the potential of Avacta’s pre|CISION® platform to provide new treatment options for SGC and other solid tumors, with further data expected in the first half of 2026.

The most recent analyst rating on (GB:AVCT) stock is a Hold with a £81.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.

Avacta Group Announces Preliminary Data in Salivary Gland Cancer Trial

Avacta Group plc announced preliminary clinical data from its Phase 1b trial of Faridoxorubicin in patients with salivary gland cancer, with detailed results to be presented on December 17, 2025. This announcement marks a significant step in Avacta’s efforts to advance its PDC technology, potentially improving treatment outcomes and positioning the company as a leader in targeted cancer therapies.

The most recent analyst rating on (GB:AVCT) stock is a Hold with a £81.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.

Avacta Unveils Innovative Dual Payload Cancer Therapy

Avacta Group PLC has unveiled its first preclinical data for its dual payload pre|CISION® technology at the 2025 AACR-NCI-EORTC International Conference. This innovative approach delivers two therapeutic payloads simultaneously to the tumor microenvironment, potentially overcoming resistance mechanisms and enhancing tumor control. The company’s dual payload pipeline includes combinations of microtubule inhibition and topoisomerase I inhibition, as well as DNA damage response agents combined with exatecan. The pre|CISION® platform has shown promising results in terms of tumor selectivity and therapeutic efficacy, offering a novel approach to cancer therapy with significant implications for treating highly-resistant tumors.

The most recent analyst rating on (GB:AVCT) stock is a Hold with a £63.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.

Avacta to Present Innovative Oncology Platform Data to Investors

Avacta Group PLC announced an upcoming presentation of their pre|CISION® dual payload peptide drug conjugate delivery system data, following their participation in the 2025 AACR-NCI-EORTC International Molecular Targets Congress. The presentation, scheduled for October 29, 2025, will be accessible to existing and potential shareholders, allowing them to engage with the company’s leadership and submit questions, potentially impacting Avacta’s market engagement and stakeholder relations.

The most recent analyst rating on (GB:AVCT) stock is a Hold with a £63.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.

Avacta Group Raises £16 Million to Advance Oncology Programs

Avacta Group plc has successfully raised approximately £16 million through an oversubscribed equity placement, which will provide additional working capital to advance its research and development programs into the second half of 2026. The funds will support the progression of the faridoxorubicin Phase 1b trial and the initiation of the FAP-EXd Phase Ia trial, while also allowing Avacta to maintain full ownership of its promising programs based on its pre|CISION® technology. This financial move also facilitates the deferment of certain convertible bond repayments, extending the company’s cash runway and enabling it to continue building its intellectual property estate.

The most recent analyst rating on (GB:AVCT) stock is a Hold with a £75.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.

Avacta’s Faridoxorubicin Shows Promising Phase 1a Results in Cancer Treatment

Avacta Group PLC announced promising results from its Phase 1a clinical trial of faridoxorubicin, presented at the European Society of Medical Oncology Annual Congress. The trial demonstrated favorable safety and tolerability, with no severe cardiac toxicity observed even at higher doses, and a significant improvement in progression-free survival for patients with salivary gland cancers. These findings highlight the potential of Avacta’s pre|CISION® platform to offer new treatment options for cancer patients, particularly those with limited therapeutic choices, and underscore the platform’s ability to protect normal tissues from toxicity while maintaining efficacy.

The most recent analyst rating on (GB:AVCT) stock is a Hold with a £75.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.

Avacta Unveils Dual-Payload Oncology Innovation

Avacta Group PLC announced the presentation of data on its first dual-payload peptide drug conjugate (PDC) at an upcoming international conference. This development marks a significant advancement in oncology therapy, as it allows for the selective and controlled release of two cancer-targeting drugs from a single molecule, potentially enhancing treatment effectiveness and addressing resistance mechanisms in tumors.

The most recent analyst rating on (GB:AVCT) stock is a Hold with a £75.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.

Avacta Group Reports Promising Interim Results and Strengthened Financial Position

Avacta Group plc has reported its interim results for the first half of 2025, highlighting significant progress in its clinical programs, particularly the faridoxorubicin (AVA6000) Phase 1b trial, which has shown promising initial clinical activity. The company has also renegotiated the terms of its Heights Convertible Bond and raised £6.5 million to fund upcoming bond payments, reflecting growing confidence in its R&D pipeline. Avacta anticipates multiple pipeline updates in late 2025, including data from its faridoxorubicin program, which could enhance its industry positioning and stakeholder interest.

The most recent analyst rating on (GB:AVCT) stock is a Hold with a £47.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.